Lyvispah (Baclofen) for Multiple Sclerosis

Overview
Lyvispah is approved by the U.S. Food and Drug Administration (FDA) for treating spasticity in people with multiple sclerosis (MS). It is particularly effective in relieving symptoms like flexor spasms, pain associated with spasms, clonus (repetitive muscle contractions), and muscular rigidity. Lyvispah is also known by its drug name, baclofen.

This drug belongs to a class of medications known as gamma-aminobutyric acid (GABA-ergic) agonists. It is believed to work by mimicking GABA, a neurotransmitter (chemical messenger) in the brain that reduces the activity of nerve cells. This action helps relax overly active muscles and reduce symptoms of spasticity.

How do I take it?
Prescribing information states that Lyvispah is taken orally as granules, with or without water, and can be mixed with soft food if consumed within two hours. It may also be administered through enteral feeding tubes. Treatment generally  begins with a low dose, taken in divided doses throughout the day, and may be gradually increased based on individual response and tolerability. It is essential to take Lyvispah exactly as prescribed by a health care provider.

Side effects
Common side effects of Lyvispah include drowsiness, dizziness, and weakness.

Rare but serious side effects may include severe withdrawal symptoms if the drug is stopped abruptly, such as seizures, confusion, or even death. Neonatal withdrawal symptoms can occur if used during pregnancy. The drug may cause drowsiness or sedation and should not be taken when operating a vehicle or dangerous machinery. Additionally, Lyvispah may worsen certain conditions, including psychotic disorders, schizophrenia, confusional states, autonomic dysreflexia (sudden high blood pressure), and epilepsy.

For more information about this treatment, visit:

Label: Lyvispah — Baclofen Granule — DailyMed